<DOC>
	<DOCNO>NCT02058433</DOCNO>
	<brief_summary>Platinum-based doublet include paclitaxel , gemcitabine , docetaxel standard 1st regimen Non-Small Cell Lung Cancer ( NSCLC ) . The traditional method individualize cytotoxic drug dose use body surface area ( BSA ) , correlate ability individual metabolize excrete cytotoxic drug , relate liver function poorly correlate glomerular filtration rate , seem determinant toxicity . Pharmacokinetic parameter area curve show correlate toxicity . The advantage use fix dose antineoplastic agent patient obvious . Pharmacokinetically guided treatment would avoid severe adverse effect , sufficiently investigate advanced NSCLC.First , investigator monitor blood concentration paclitaxel neutropenia blood toxicity chemotherapy paclitaxel carboplatin patient NSCLC verify suitable paclitaxel therapeutic window Chinese patient . Then investigator compare safety efficacy individual paclitaxel dose adjustment base therapeutic window compare conventional dosage .</brief_summary>
	<brief_title>Safety Study Individual Paclitaxel Dose Adjustment Based Pharmacokinetics Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Primary end point : Common Terminology Criteria Adverse Events ( CTCAE ) grade 4 . Secondary end point : Objective Response Rate ( ORR ) , Progression Free Survival ( PFS ) , Overall Survival ( OS ) , Quality Of Life ( QOL ) etc .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>For inclusion study treatment period patient must fulfil follow criterion : 1 . Provision informed consent . 2 . Male female age 18 year . 3 . Histologically cytologically confirm nonsmall cell lung carcinoma . 4 . Locally advanced Stage amenable local therapy ( e.g . pleural effusion ) metastatic disease . 5 . No prior chemotherapy , biological ( include target therapy Epidermal Growth Factor Receptor ( EGFR ) Vascular Epidermal Growth Factor ( VEGF ) inhibitor ) immunological therapy . Patients willing accept paclitaxel carboplatin adjuvant chemotherapy eligible . 6 . World Health Organization ( WHO ) performance status ( PS ) 0 2 . 7 . Females childbearing potential must negative serum pregnancy test . Sexually active male female ( childbearing potential ) willing practice contraception study . 8 . Laboratory value within range , define , within two week randomization : Absolute neutrophils count ( ANC ) ≥2.0×109/L Platelets≥100×109/L Serum bilirubin≤2×ULN ; Aspartate transaminase ( AST ) alanine tansaminase ( ALT ) ≤2.5×ULN ( ≤5×ULN liver metastasis ) Creatinine clearance≥60ml/min 9 . Measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) criteria least one measurable lesion previously irradiate . 10 . Life expectancy ≥12 week . Any follow regarded criterion exclusion study : 1 . As judged investigator , evidence severe uncontrolled systemic disease ( e.g . unstable uncompensated respiratory , cardiac , hepatic renal disease ) . 2 . Newly diagnosed Central Nervous System ( CNS ) metastases yet definitively treat surgery and/or radiation . 3 . Known severe hypersensitivity carboplatin , paclitaxel excipients products.Known severe hypersensitivity premedications require treatment carboplatin / paclitaxel doublet chemotherapy . 4 . Prior treatment paclitaxel . 5 . Current treatment target drug biological therapy . 6 . Pregnant lactate woman . 7 . Prior chemotherapy , biological ( include target therapy Epidermal Growth Factor Receptor ( EGFR ) Vascular Epidermal Growth Factor ( VEGF ) inhibitor ) immunological therapy receive even treatment paclitaxel complete 4 week day1 study treatment . 8 . Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ . 9 . Life expectancy le 12 week . 10 . Unable tolerate carboplatin / paclitaxel doublet chemotherapy , judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>Individual Paclitaxel dose</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>